Preconditioning by N-methyl-d-aspartate (NMDA) may be promoted in vivo by the administration of a sub-convulsing dose of NMDA, with a neuroprotective effect against seizures and neuronal death induced by the infusion of quinolinic acid (QA) in mice. This study aimed to evaluate the participation of protein kinase C (PKC), cyclic AMP-dependent protein kinase (PKA), mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK), Ca 2+ /calmodulin dependent protein kinase II (CaMKII) and phosphatidilinositol-3 kinase (PI3K) signaling pathways in this neuroprotection model. Adult Swiss male mice were preconditioned with NMDA 24 h before the infusion of QA, and were treated with inhibitors of the aforementioned signaling pathways either 15 min before the preconditioning or infusion of QA. Inhibition of the PKA and PI3K pathways abolished the protection evoked by NMDA, and inhibition of the MEK pathway significantly diminished this protection. Treatment with PKC and CaMKII inhibitors did not alter the protection rate. Inhibition of the MEK and PKC pathways resulted in an increased mortality rate when followed by the infusion of QA, or NMDA preconditioning and QA infusion, respectively. These results suggest that the PKA, PI3K and MEK pathways have a crucial role in the achievement of a neuroprotective state following preconditioning.
Introduction
Brain preconditioning refers to a state of transient tolerance of the brain tissue to a lethal insult that can be evoked by a prior mild insult [1] . Chemical preconditioning by N-methyl-d-aspartate (NMDA) has been shown to protect neurons in vitro [2] and in vivo [3, 4] against posterior insults. In vitro, a subtoxic concentration of NMDA was seen to prevent neuronal death induced by glutamate, NMDA [2, 5, 6] or oxygen and glucose deprivation [7, 8] . In vivo, NMDA preconditioning can be evoked by a nonconvulsant dose of NMDA, and this application is known to be neuroprotective against kainate-induced toxicity [9] or ischemia [10] . NMDA preconditioning prevents seizures and neuronal death induced by quinolinic acid (QA) in mice [3] . Despite the well known neuroprotective effects of NMDA, the neural mechanisms involved in NMDA preconditioning remain unknown.
It is thought that the preconditioning may induce signaling cascades that activate effector mechanisms responsible for neuroprotection. These mechanisms may involve the attenuation of cell damage pathways such as excitotoxicity, ionic unbalance, oxidative and nitrosative stress, metabolic disfunction, inflammation and processes related to necrotic and apoptotic cell death [11] . Besides, it is believed that this protection could be obtained through activation and/or upregulation of survival and repair mechanisms such as antioxidant enzymes, heat-shock proteins, DNA repair proteins, and antiapoptotic Bcl-2 family members [1] .
The cell signaling cascades inducing upregulation of survival pathways or downregulation of necrotic and apoptotic pathways are not completely known, although some studies have provided us with some insights. Previous studies have related protein kinase C (PKC) and the mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK) to the tolerance promoted by preconditioning, since inhibition of PKC and MAPK/ERK kinase (MEK), which phosphorylates and activates ERK1 and ERK2, abolishes the neuroprotective effect of NMDA preconditioning in vitro against the toxicity of oxygen glucose deprivation [12] . Protein kinase A (PKA) activation has been shown to be necessary in the heart ischemic and desflurane-induced preconditioning models through the activation of cyclic AMP response element binding protein (CREB) [13, 14] . High-K + -induced preconditioning has been shown to involve Ca 2+ /calmodulin dependent protein kinase II (CaMKII) in neuronal cultures exposed to oxy- gen glucose deprivation [15] . Miyawaki et al. [16] have shown that phosphatidilinositol-3 kinase (PI3K) and inhibition of the downstream protein kinase B (PKB or Akt) reduces neuroprotection induced by brain ischemic preconditioning against cerebral global ischemia.
QA, an endogenous tryptophan metabolite, is a well known NMDA receptor agonist that can cause excitotoxicity. QA cytotoxicity has been attributed to elevation of cytosolic concentrations of free Ca 2+ , mitochondrial disfunction and the formation of free radicals [17, 18] . QA toxicity has been implicated in a wide gamut of pathological conditions, such as Huntington's and Parkinson's diseases [19] , and in the etiology of epilepsy in humans [20] . It has been previously shown that QA can also overstimulate the glutamatergic system through modulation of glutamate transport, given that it is capable of inhibiting glutamate uptake in cultured astrocytes [21] and decreasing glutamate uptake into synaptic vesicles [22] . Cerebro-ventricular administration of QA has been used as a model of induction of clonic-tonic seizures [23] , and it is known to cause neural hippocampal death in mice [24] and reduce hippocampal glutamate uptake [25] .
As previously demonstrated, NMDA preconditioning can prevent seizures and neural death in the hippocampus after an intracerebroventricular (i.c.v.) infusion of QA [3, 4] , although the signaling cascades involved in this state of tolerance induced by NMDA preconditioning in the brain are not known. Therefore, the aim of this study was to evaluate the possible participation of the PKC, CaMKII, PKA, PI3K and MEK/ERK signaling pathways in the NMDA preconditioning against QA-induced seizures.
Materials
) and PD98059 were purchased from Sigma (St. Louis, MO, USA). Chelerythrine and wortmannin were purchased from Alomone (Jerusalem, Israel). The anesthetic sodium thiopental was obtained from Cristalia (Itapira, SP, Brazil).
Animals
Male adult Swiss albino mice (30-40 g ) were maintained on a 12 h light/12 h dark schedule (lights on at 7:00 a.m.) at 25
• C. Mice were housed in plastic cages with food and water ad libitum. All experiments were designed to minimize animal suffering and to limit the number of animals used and were approved by the local Ethical Committee for Animal Research.
Surgical procedure
Animals were anesthetized with sodium thiopental (60 mg/kg; 10 ml/kg; i.p.). Stereotaxic surgery and infusion techniques were carried out as previously described in Schmidt et al. [23] . Briefly, in a stereotaxic apparatus, the skin of the skull was removed and a 27-gauge/7-mm guide cannula was placed at 1 mm posterior to bregma, 1 mm right from midline and 1 mm above the lateral brain ventricle. The guide cannula was implanted 1.5 mm ventral to the superior surface of the skull and fixed with jeweler acrylic cement. The tip of the 30-gauge infusion cannula protruded 1 mm beyond the guide cannula, aiming for the lateral ventricle. Methylene blue (4 l) was injected through the cannula to confirm the effectiveness of the infusions. Animals without contrast in the lateral brain ventricle were discarded.
Treatment with inhibitors
Selective inhibitors for the effector kinases of intracellular pathways were infused i.c.v. In this study we used chelerythrine (1 g/site, 4 l) selective for PKC, H-89 (1 g/site, 4 l) selective for PKA, PD98059 (5 g/site, 4 l) selective for MAPK/ERK kinase (MEK), KN-62 (1 g/site, 4 l) selective for CaMKII and wortmannin (0.43 g/site, 4 l) selective for PI3K. All drugs were dissolved in saline 0.9% and were injected 15 min before NMDA preconditioning or 15 min before QA i.c.v. infusion. The doses of the chelerythrine, H-89, KN-62 and PD98059 were based on the study of Almeida et al. [26] and wortmannin was based on the study of Ozaita et al. [27] . After the infusion of the inhibitors, animals were observed for 10 min for the occurrence of behavioral changes.
NMDA preconditioning and QA infusion
NMDA was dissolved in saline solution (NaCl 0.9 g%) and adjusted to pH 7.4 with NaOH. Animals were pretreated with NMDA at a low nonconvulsant dose (75 mg/kg; 10 ml/kg; i.p.) [3] or vehicle (saline; 10 ml/kg, i.p.) 24 h before QA or saline i.c.v. administration. Animals were observed for 30 min immediately after the administration of NMDA. Chemical seizures were induced by infusion of QA (4 l, 36.8 nmol; i.c.v.) [23] . Mice were observed for 10 min for the occurrence of wild running, clonic, tonic, or tonic-clonic seizures lasting more than 5 s. Mice not displaying seizures during these 10 min were considered protected. As previously reported by Boeck et al. [3] , NMDA preconditioning 24 h prior to QA infusion evoked a protection rate of 53% against the incidence of seizures (non-convulsed mice, NQnc). Also, those animals in which NMDA preconditioning did not exert protection (convulsed mice, NQc) showed no alteration neither in latency nor in duration of seizures when compared to the QA group.
Statistical analysis
Incidence of seizures were analyzed by Fisher's exact test, p < 0.05. Seizure latency and duration were analyzed by a one-way analysis of variance (ANOVA) followed by Tukey's post hoc test. Differences were considered significant at >95% confidence.
Results
It has been previously shown that 36.8 nmol of QA administered i.c.v. induces 100% of seizures in mice [3, 4] . Additionally, it has been observed that NMDA preconditioning is able to prevent QA-induced seizures and cell death in almost 50% of the animals. In this study we were interested in evaluating the effect of inhibitors of several intracellular signaling pathways on the protection induced by NMDA preconditioning against QA-induced seizures.
To evaluate the effect of the PKC signaling pathway, we used chelerythrine, a non-specific PKC inhibitor capable of inhibiting all isoforms of PKC. No seizures were observed in the control mice (Sal + Ch). Infusion of chelerythrine i.c.v. 15 min before NMDA preconditioning promoted a partial reduction of NMDA preconditioning-induced seizures protection from 46.8% to 26.6%, which was considered non-significant by Fisher's exact test (Fig. 1A) . Treatment with chelerythrine before QA infusion did not alter the incidence of seizures (Fig. 1A) . The evaluation of the percentage of mice dead after seizures showed that treatment with chelerythrine before QA (Ch + QA group) and before NMDA and QA (Ch + NMDA + QA) promoted a mortality rate of 100% and 60%, respectively. This mortality rate was statistically different from saline plus QA and NMDA plus QA groups (Fig. 1B) .
In the same way, we used KN-62 to inhibit the CaMKII pathway. Infusion of KN-62 did not induce seizures in the control mice (Sal + Ch). I.c.v. infusion of KN-62 non-significantly reduced NMDA preconditioning-evoked protection from 46.6% to 26.6% ( Fig. 2A) . Administration of KN-62 before QA infusion did not alter the incidence of QA-induced seizures ( Fig. 2A) . KN-62 treatment also did not alter the mortality rate when compared to saline plus QA and NMDA plus QA groups (Fig. 2B) .
Infusion of H-89, a PKA inhibitor, totally abolished the NMDA preconditioning-evoked protection against QA-induced seizures (Fig. 3A) . H-89 administered before QA promoted a non-significant 14.3% reduction in the QA-induced seizures. No seizures were observed in the control mice (Sal + H-89) (Fig. 3A) .
The same abolishment of the NMDA-induced protection was observed when wortmannin, a PI3K inhibitor, was administered before the NMDA preconditioning (Fig. 4A) . Wortmannin treatment 15 min before QA infusion did not alter the incidence of seizures (Fig. 4A) . No seizures were observed in the control mice (Sal + Wort). Treatment with H-89 and wortmannin did not significantly alter the mortality rate when compared to saline plus QA and NMDA plus QA groups (Figs. 3B and 4B, respectively) .
Infusion of a selective MEK inhibitor (PD098059) promoted a significant reduction of the NMDA preconditioning-induced neu- roprotection from 46.6% to 12.5% (Fig. 5A) . PD098059 administered before QA resulted in a non-significant reduction of the QAinduced seizures. No seizures were observed in the control mice (Sal + PD) (Fig. 5A) . QA infusion after PD98059 treatment (PD + QA group) promoted an elevated mortality rate significantly different from saline plus QA and NMDA plus QA groups (Fig. 5B) . Treatment with PD98059 before NMDA preconditioning and QA infusion (PD + NMDA + QA group) was not different from other groups (Fig. 5B) .
Inhibition of the PKC, CaMKII, PKA, PI3K and MAPK/ERK signaling pathways did not alter either latency or duration of QA-induced seizures (Table 1) .
Discussion
QA is a NMDA receptor agonist involved on cellular toxicity through an increase in the production of free radicals, disruption of glutamatergic transmission, and is associated with a wide range of brain pathologies [28] . In this study we aimed to evaluate the participation of intracellular signaling pathways in the induction of a tolerance state evoked by chemical preconditioning by NMDA, as well as their role in the seizures caused by the i.c.v. infusion of QA.
The PKC signaling pathway has been related to cell survival and death. Chou and Messing [29] and Barnett et al. [30] demonstrated that some PKC isoforms more prevalent in the brain have been implicated with cell death or survival, depending on the isoform and the model evaluated. PKC is related to glutamatergic excitotoxicity, and its inhibition was found to be neuroprotective in a model of pretreatment with estrogen [31] , while PKC␥ was shown to be a positive effector in the same model [32] . On the other hand, PKC has been implicated in the protection promoted by ischemic preconditioning since its inhibition totally abolished the preconditioning-induced protection, and its activation promotes a protection similar to that of ischemic preconditioning [33] .
The infusion of chelerythrine before QA promoted a mortality rate of 100% (Fig. 1B) which demonstrates the importance of this family of kinases in cell survival. On the other hand, infusion of chelerythrine before NMDA preconditioning did not alter the protection rate against QA-induced seizures (Fig. 1A) , demonstrating that the PKC signaling pathway does not contribute to that protection.
The CaMKII signaling pathway has been related to neuronal protection against intracellular Ca 2+ disturbances in glutamatergic excitotoxicity models [34, 35] . Here, it was shown that KN-62 infusion partially reduced the NMDA preconditioning-evoked protection ( Fig. 2A) , which was not considered to be statistically significant. In the same way, Tauskela et al. [36] observed that the inhibition of CaMKII also partially abolished the protection in ischemic and NMDA preconditioning models in mice cortical neuron cultures. However, Carter et al. [34] demonstrated that a reduction in the activation of the CaMKII signaling pathway promoted the occurrence of spontaneous epileptiform discharges.
It has been previously demonstrated that the activation of NMDA receptors promotes the activation of PKA [37] and PKA modulation of the permeability of NMDA receptors to Ca 2+ [38] . The results shown in Fig. 3A also suggest a relationship between the activation of NMDA receptors and the activation of PKA, since H-89 infusion completely abolished the neuroprotection against seizures evoked by NMDA preconditioning. Tang et al. [48] suggested that the activation of PKA promotes an increase in the phosphorylation of the NMDA receptor NR1 subunit and its expression on the surface of the membrane. Besides, other studies have pointed that the activation of PKA induces an increase on the expression of AMPA receptors in synaptic terminals through phosphorylation of the GluR1 subunit [39, 40] . Therefore, a comprehensive evaluation of the expression of NMDA and AMPA receptors might be of great help in understanding the role of PKA in this preconditioning model.
The activation of NMDA receptors has been shown to induce activation of the PI3K signaling pathway, and consequently the phosphorylation of Akt(PKB) through a Ca 2+ -dependent process [10, 41] . Other studies have also shown that the PI3K signaling pathway is involved in cell survival [42] . In the present study, we have shown that wortmannin completely prevented the protection evoked by NMDA preconditioning. These data are consistent with the studies of Soriano et al. [43] , which demonstrate that a low neuroprotective dose of NMDA promotes neuronal protection against excitotoxic insults through activation of the PI3K/Akt pathway. Additionally, Miao et al. [10] have shown that neuroprotection against global ischemia can be attained in an ischemic precondi- tioning model by the activation of Akt through NMDA receptors. Thus, it has become clear that the activation of the PI3K signaling pathway is crucial for the induction of neuroprotection in preconditioning models.
Activation of the MAPK/ERK signaling pathway through NMDA receptors is associated to the occurrence of long term potentiation (LTP), since PD98059 (MEK inhibitor) is capable of preventing the establishment of LTP [44] . The results obtained herein also demonstrate a relationship between the MAPK/ERK pathway and NMDA receptors, since a pretreatment with PD98059 promoted a partial reduction in the protection evoked by NMDA preconditioning (Fig. 5A) . Furthermore, we would like to point out that the observed reduction could be underestimated since PD98059 is actually an inhibitor of MEK, the kinase upstream from ERK. Corroborating this hypothesis, studies by Gao et al. [45] suggested the existence of a crosstalk between the ERK and PKC pathways, in a way that ERK could be activated despite the inhibition of MEK. We also observed that the inhibition of MEK by PD98059 before infusion of QA promoted a mortality rate similar to that observed for chelerythrine (Figs. 1B and 5B) , further suggesting that the involvement of both the MAPK/ERK and PKC signaling pathways in the processes of cell recovery and survival in response to a excitotoxic insult such as the infusion of QA. Mortality rate was not altered when PD98059 was administered before NMDA preconditioning, implicating that NMDA receptors activation could involve other signaling pathways that promote cell survival or prevent cell death. Studies carried out by Youssef et al. [46, 47] have shown that the activation of NMDA receptors hinders the occurrence of LTP and desensitizes these receptors to subsequent stimuli, an effect that could be reversed by the inhibition of nitric oxide synthase (NOS). These studies indicate that the production of NO may play an important role in the achievement of a neuroprotective state. Taken together with the data presented herein, these data suggest that elucidating the modulation and role of cellular signaling pathways is a promising step in clarifying the mechanisms responsible for the obtention of a stable state of neuroprotection. In summary, the present study has demonstrated that the PKA, PI3K and MAPK/ERK, but not the CaMKII and PKC signaling pathways prevented the neuroprotection against QA-induced seizures evoked by NMDA preconditioning. Similarly, we observed that the PKC and MAPK/ERK pathways could be involved in the cell response to the glutamatergic agonist QA, as it was shown that PKC and MEK inhibition before QA-induced seizures results in an increased mortality rate. Taken together these results do not, however, rule out the involvement of other intracellular signaling pathways, such as the p38 MAK and c-Jun N-terminal kinase (JNK) pathways, that could be investigated in future approaches.
